生长抑素对急性胰腺炎患者血清抵抗素的影响

目的]观察生长抑素对急性胰腺炎(AP)患者血清抵抗素水平的影响。方法]选择AP患者54例,随机分为基础治疗亚组(28例)和生长抑素治疗亚组(26例),以正常健康人40例为正常对照组。基础治疗亚组给予包括重症监护,应用抗生素,改善脏器微循环,加强对症、支持等治疗;生长抑素治疗亚组在基础治疗的同时加用生长抑素针。所有入选研究者分别于治疗前、治疗后d3、d7测定APACHEⅡ积分、血清高敏C-反应蛋白(hs-CRP)和抵抗素水平。结果]①治疗前MAP与SAP患者的血清抵抗素水平与hs-CRP浓度均较正常对照组显著升高(P﹤0.01),但SAP患者升高较MAP更为明显(P﹤0.01)。②治疗后d3,基础治疗亚组和生长抑素治疗亚组的抵抗素水平较治疗前进一步增加(P﹤0.01),但是APACHEⅡ积分与治疗前对比无明显差异(P﹥0.05)。③治疗后d7时,基础治疗亚组和生长抑素治疗亚组的抵抗素水平和APACHEⅡ积分均较治疗d3时明显下降(P﹤0.05),且与基础治疗亚组比较,生长抑素治疗亚组降低更为显著(P﹤0.05)。结论]生长抑素能够降低血清抵抗素水平,减轻炎症反应,改善AP患者的病情严重程度。

EFFECT OF SOMATOSTATIN ON SERUM RESISTIN IN PATIENTS WITH ACUTE PANCREATITIS

Objective]To observe the effect of somatostatin on serum concentrations of resistin in patients with acute pancreatitis(AP).Methods]54 patients with AP were divided to basic treatment sub-group(n=28)and somatostatin sub-group(n=26),and 40 healthy subjects were selected to control group.Patients in the basic treatment sub-group were given basic treatment including intensive care,antibiotics,improving organ microcirculation,strengthening symptomatic and support treatment.Patients in the somatostatin treatment subgroup were given somatostatin besides basic treatment.APACHE Ⅱ scores,high sensitivity C-reactive protein(hs-CRP)and resistin were determined respectively before treatment and at the third,seventh day after treatment in all patients.Results]① Serum levels of resistin and hs-CRP in the MAP and SAP patients were significantly higher than those in the control group before treatment(P﹤0.01),and increases of resistin and hs-CRP in the SAP patients was more obvious compared to that in the SAP patients.② Compared with that before treatment,resistin levels were increased at the third day after treatment in the basic treatment subgroup and the somatostatin subgroup(P﹤0.01),but APACHE Ⅱ scores were not significantly different(P﹥0.05).③ Although compared to those at the third day after treatment,resistin levels and APACHE Ⅱ scores were decreased at the seventh day after treatment in the basic treatment subgroup and the somatostatin subgroup(P﹤0.05),decreases of resistin levels and APACHE Ⅱ scores in the somatostatin subgroup were more obvious compared to those in the basic treatment subgroup.Conclusion]Somatostatin can improve the severity of AP by decreasing serum resistin level and alleviating inflammation.